Merck & Co., Inc.

🇺🇸New York Stock Exchange
Back to all articles
Merck & Co., Inc. stock analysis MRK overview
Bullish +75

Merck Stock Rises 6% as Lung Cancer Treatment Cuts Tumor Progression Risk Significantly - TIKR.com

📈 Merck stock jumped 5.6% to close at $122.41 following positive clinical and regulatory news.

🇪🇺 European health officials recommended approving the Keytruda and Padcev combination for muscle-invasive bladder cancer patients.

💊 Sac-TMT, an ADC licensed from Kelun Pharma in 2022, demonstrated a 70% response rate when combined with Keytruda in lung cancer trials.

📉 The new regimen cut the risk of disease progression by 53% in patients with high PD-1 protein levels compared to standard care.

🔬 Standard chemo-plus-Keytruda regimens showed a 56%-58% response rate, making the combination therapy significantly more effective.

👴 The bladder cancer approval targets elderly or frail patients who previously had very few treatment options available.

🧠 Analysts view Sac-TMT as a key answer to investor concerns about Keytruda's future revenue once patent exclusivity expires.

🚀 Leerink Partners analyst Daina Graybosch stated the results support Merck's 'bio-better chemo' strategy and met market expectations.

💼 The developments suggest the market is starting to price in a diversified oncology pipeline beyond just Keytruda.

Bullish Signals
  • Merck received a European recommendation for its Keytruda and Padcev combination for muscle-invasive bladder cancer, expanding its addressable patient population.
  • The Sac-TMT + Keytruda combination achieved a 70% response rate in lung cancer trials, significantly outperforming the 56%-58% response rate of standard chemotherapy regimens.
  • The new therapy reduced the risk of disease progression by 53% in high PD-1 protein patients, demonstrating superior efficacy over current standards of care.
  • Analysts confirm that Sac-TMT results validate Merck's 'bio-better chemo' strategy, addressing long-term concerns about post-Keytruda patent revenue.
  • The stock price reaction indicates the market is beginning to value a more diversified oncology pipeline that does not rely entirely on Keytruda.
Full Analysis
Merck (MRK) shares rose 5.6% to close at $122.41 on Friday, driven by two significant oncology developments. First, European health officials recommended approving Merck's combination of Keytruda and Padcev for patients with muscle-invasive bladder cancer. This recommendation is particularly impactful as it offers a viable treatment option for elderly or frail patients who often cannot tolerate harsh chemotherapy regimens. Second, the company released late-stage trial results for Sac-TMT, an antibody-drug conjugate (ADC) licensed from China's Kelun Pharma in 2022. When combined with Keytruda, the regimen showed a 70% response rate in lung cancer patients, compared to 56%-58% for standard chemo-plus-Keytruda regimens. Furthermore, the combination reduced the risk of disease progression by 53% in patients with high levels of the PD-1 protein. These results address long-standing investor concerns regarding Merck's reliance on Keytruda as its primary revenue driver ahead of patent exclusivity loss. Analysts from Leerink Partners noted that the data met expectations and supports Merck's 'bio-better chemo' strategy, suggesting the market is beginning to price in a more diversified oncology pipeline that reduces dependency on a single blockbuster drug.